The Reality of Weight Loss Injections: Does Wegovy Work on Everyone?

Last reviewed: June 18, 2026

Last updated: June 18, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide injections have demonstrated weight loss efficacy in clinical trials, with participants losing 10–22% of body weight over 68 weeks depending on study cohort. However, not every person experiences the same degree of success with GLP-1 therapy. Understanding why certain individuals respond more robustly than others requires looking beyond medication alone and into individual biological factors that shape treatment outcomes.

Why Weight Loss Injection Results Vary Between Individuals

Response variation to semaglutide and other GLP-1 medications stems from multiple biological systems rather than a single mechanism. Genetic differences in appetite-regulating pathways, metabolic rate genes, and insulin sensitivity all influence how effectively a medication reduces hunger signals and improves weight management. Additionally, baseline body composition, lifestyle adherence, sleep quality, and stress levels create unique metabolic environments that either amplify or diminish the medication's effectiveness.

Research shows approximately 30–40% of individuals may experience a suboptimal response to standard GLP-1 therapy, while others achieve dramatic results with the same dose. This variation is neither random nor purely dose-dependent; it reflects genuine differences in how each person's biology processes appetite suppression and metabolic change. Recognizing this reality moves treatment away from a one-size-fits-all model toward individualized strategies that account for personal risk factors and genetic predispositions.

Genetic Factors That Influence Semaglutide Injection Effectiveness

Four key genetic variants significantly shape how your body responds to GLP-1 medications. The GLP1R rs6923761 variant affects the GLP-1 receptor's sensitivity to the medication itself. The GIPR rs1800437 variant influences glucose-dependent insulinotropic peptide signaling, which modulates hunger and satiety independently. The FTO rs9939609 variant relates to baseline metabolic rate and fat storage tendency. The MC4R rs17782313 variant plays a central role in melanocortin pathway signaling, which regulates overall energy balance through the brain's appetite centers.

The PlexusDx Precision Peptide Genetic Test ($298) analyzes GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to semaglutide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Clinical Evidence on Semaglutide Success Rates and Individual Outcomes

The STEP clinical trial program demonstrated that approximately 70% of participants achieved at least 5% weight loss with semaglutide 1.0 mg weekly, while 51% reached 10% loss and 35% achieved 15% or greater loss. These outcomes represent aggregate data; individual trajectories ranged from minimal change to losses exceeding 22% body weight. The trial also revealed that early responders—those showing significant appetite reduction within the first 4 weeks—typically sustained greater long-term success compared to delayed responders.

A smaller subset of trial participants experienced gastrointestinal side effects severe enough to discontinue treatment, illustrating that tolerability also varies individually. Factors including prior medication exposure, gut microbiota composition, and stress sensitivity influenced whether side effects remained mild or became limiting. Understanding your personal risk profile for both efficacy and side effects allows treatment adjustments before they become problematic, emphasizing the value of personalized dosing strategies and monitoring.

Optimizing Your Semaglutide Treatment for Maximum Personal Response

PlexusDx provides compounded semaglutide injections at $189/mo month-to-month, or from $149/mo on the 6-month plan, with pricing held constant regardless of your dose escalation—meaning your dose may need to go up, but your price won't. This pricing model removes the financial barrier to dose optimization, allowing your prescriber to adjust your medication based on your individual response rather than cost constraints. PlexusDx serves all 50 states without insurance requirements and accepts HSA and FSA payments for added affordability.

Maximizing your personal response involves three parallel strategies: consistent weekly injection administration, documented appetite and weight tracking to identify your response pattern within the first 8–12 weeks, and optional genetic testing through the Precision Peptide Genetic Test to confirm your predicted responder status. If early response is suboptimal, your prescriber may recommend combination therapy using PlexusDx's GLP-Squared Injection, which combines semaglutide with tirzepatide to engage dual GLP-1 and GIP pathways. Regular follow-up ensures your dose, medication formulation, and adjunctive lifestyle support align with your evolving metabolic needs.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

If I don't respond well to semaglutide, what are my other options?

PlexusDx offers tirzepatide injection (a dual GLP-1/GIP agonist) at $289/mo month-to-month, or from $249/mo on the 6-month plan, or the GLP-Squared Injection combining both compounds for enhanced pathway engagement. Your prescriber can also recommend oral formulations or the Microdose GLP-1 Protocol at $129/month. Genetic testing through the Precision Peptide Genetic Test helps describe the pathway-level variants involved.

What percentage of people actually lose weight on semaglutide?

No — the Precision Peptide Genetic Test does not predict your response to semaglutide or any specific medication. It analyzes pathway-level variants (GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

How much does PlexusDx compounded semaglutide cost compared to brand-name Wegovy?

PlexusDx compounded semaglutide injections are $189/mo month-to-month, or from $149/mo on the 6-month plan from licensed 503A compounding pharmacies, with no insurance required and HSA/FSA eligibility. Brand-name Wegovy often costs $900–$1,500/month without insurance coverage. PlexusDx pricing remains flat regardless of dose escalation—your dose may need to go up, but your price won't.

Are compounded semaglutide injections as safe and effective as brand-name options?

No — the Precision Peptide Genetic Test does not predict your response to semaglutide or any specific medication. It analyzes pathway-level variants (GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

How does the Precision Peptide Genetic Test relate to your GLP-1 pathway?

No — the Precision Peptide Genetic Test does not predict your response to Wegovy or any specific medication. It analyzes pathway-level variants (GIPR (rs1800437), FTO (rs9939609), and MC4R (rs17782313)) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Related Reading

• Wegovy Weight Loss Injections
• Wegovy For Weight Loss 2
• Wegovy Weight Loss Pills
• Wegovy Vs Zepbound Weight Loss

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.